SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-145622
Filing Date
2020-05-19
Accepted
2020-05-19 08:15:40
Documents
14
Period of Report
2020-05-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d931964d8k.htm   iXBRL 8-K 49270
2 EX-99.1 d931964dex991.htm EX-99.1 26422
6 GRAPHIC g931964g0518120244460.jpg GRAPHIC 2994
  Complete submission text file 0001193125-20-145622.txt   214417

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20200518.xsd EX-101.SCH 3066
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20200518_lab.xml EX-101.LAB 17373
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20200518_pre.xml EX-101.PRE 10950
13 EXTRACTED XBRL INSTANCE DOCUMENT d931964d8k_htm.xml XML 3237
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 20891619
SIC: 2834 Pharmaceutical Preparations